4 Ways Your Medicare Part D Plan May Have Changed in 2026

Medicare Part D plans commonly changed for 2026, with the article noting likely increases in monthly premiums, higher annual deductibles, upward movement of drugs into higher formulary tiers (raising copays), and alterations to preferred pharmacy networks that can substantially raise out-of-pocket costs. For investors, the primary implication is increased cost pressure on retirees' budgets and potential enrollment shifts that could modestly affect retail pharmacies, PBMs and plan sponsors, though the piece contains no company-specific financial data and is unlikely to be market-moving on its own.

Analysis

Market structure: Annual Part D churn (premiums, deductibles, formularies, preferred-pharmacy shifts) benefits scale players that control PBMs + retail networks (UNH/Optum, CVS/Caremark, CI/Express Scripts, WMT pharmacy) and mail-order/generic manufacturers (TEVA). Small independents and non-preferred pharmacies lose volume and pricing power; expect a 3–8% reallocation of script volume toward preferred networks over 12–24 months, compressing margins for outsiders.

Risk assessment: Key tail risks are regulatory (expanded Medicare drug-price negotiation, state reimbursement caps, DOJ PBM probes) and contract renewals (major plan wins/losses). Immediate catalysts are CMS plan/formulary data and insurer Q3/Q4 results (next 30–90 days); medium-term (6–18 months) risks include IRA expansion or adverse litigation that could cut PBM rebate economics by >20%.

Trade implications: Favor overweight positions in integrated insurers/PBMs (UNH, CVS) and large retailers with low-cost pharmacy offerings (WMT); underweight/short small-cap pharmacy operators (RAD) and mom-and-pop pharmacy cohorts. Use calendar/timing play around CMS dataset releases (enter 4–8 weeks before release, trim 3–6 months after enrollment settles). Expect elevated options implied vol into announcements—use call spreads to limit cost.

Contrarian angles: Market may over-penalize PBMs on regulatory headlines—discounts >10% could be buying opportunities given sticky rebates and administrative scale. Conversely, the consensus may underweight the acceleration to mail-order/generic substitution (benefits TEVA, AMZN/FDA-compliant directories) which could re-rate low-cost-distribution players if net-new mail-order penetration rises >5% yearly.

Key Decisions for Investors

• Establish a 2–3% long position in UNH (UnitedHealth) within the next 30–60 days to capture Optum Rx share wins; add on any pullback >5%; target +12–18% 6–12 months, stop-loss 8%.
• Initiate a 2% long in CVS (CVS) or a directional Nov 6–9 month call spread (buy ATM, sell 10–15% OTM) sized to 0.5–1% of portfolio to play vertical integration and preferred-network capture into open enrollment.
• Short a 1% position in RAD (Rite Aid) or a basket of independent-pharmacy equities; set a tactical target of -20–30% within 6 months and a hard stop-loss at +12% to reflect network-traffic erosion risk.
• Use options hedges: buy 3–6 month puts on small-pharmacy exposure (RAD) sized to 0.5% if gross exposure >1%; alternatively buy 3–9 month call spreads on UNH/CVS sized 0.5–1% to exploit elevated IV before CMS formulary/plan-data releases.
• Monitor CMS Part D plan/formulary data releases and IRA negotiation list announcements over the next 30–90 days. If CMS datamart shows >5% incremental script consolidation to top-3 PBMs, increase UNH/CVS allocations by +1% each within 2 weeks.